JP2022548764A5 - - Google Patents
Info
- Publication number
- JP2022548764A5 JP2022548764A5 JP2022517990A JP2022517990A JP2022548764A5 JP 2022548764 A5 JP2022548764 A5 JP 2022548764A5 JP 2022517990 A JP2022517990 A JP 2022517990A JP 2022517990 A JP2022517990 A JP 2022517990A JP 2022548764 A5 JP2022548764 A5 JP 2022548764A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- sequence
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306148.8 | 2019-09-20 | ||
| EP19306148 | 2019-09-20 | ||
| PCT/EP2020/076198 WO2021053199A1 (en) | 2019-09-20 | 2020-09-18 | Single-domain antibodies directed against lilrb2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548764A JP2022548764A (ja) | 2022-11-21 |
| JP2022548764A5 true JP2022548764A5 (enExample) | 2023-09-25 |
| JP7627687B2 JP7627687B2 (ja) | 2025-02-06 |
Family
ID=68654426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517990A Active JP7627687B2 (ja) | 2019-09-20 | 2020-09-18 | Ｌｉｌｒｂ２に対するシングルドメイン抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235050A1 (enExample) |
| EP (1) | EP4031572A1 (enExample) |
| JP (1) | JP7627687B2 (enExample) |
| KR (1) | KR20220128332A (enExample) |
| CN (1) | CN115066435B (enExample) |
| AU (1) | AU2020351274A1 (enExample) |
| BR (1) | BR112022004534A2 (enExample) |
| CA (1) | CA3154450A1 (enExample) |
| IL (1) | IL291506A (enExample) |
| MX (1) | MX2022003365A (enExample) |
| WO (1) | WO2021053199A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119156229A (zh) * | 2022-03-04 | 2024-12-17 | D2M生物治疗有限公司 | 抗lilrb1/2抗体及其用途 |
| CN114805580B (zh) * | 2022-06-28 | 2022-09-06 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN115975029B (zh) * | 2022-06-28 | 2026-05-29 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| WO2024022462A1 (zh) * | 2022-07-29 | 2024-02-01 | 盛禾(中国)生物制药有限公司 | 一种抗ilt4的单域抗体及其应用 |
| AU2023328075A1 (en) * | 2022-08-22 | 2025-04-03 | Antengene Biologics Limited | Novel anti-lilrb2 antibodies and uses thereof |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN116789826A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗人lilrb2全人源单域抗体及其应用 |
| CN116789825B (zh) * | 2023-05-12 | 2026-06-02 | 南京师范大学 | 抗lilrb1/lilrb2的全人源单域抗体及其应用 |
| CN119176874A (zh) * | 2023-06-21 | 2024-12-24 | 康源博创生物科技(北京)有限公司 | 一种能够结合lilrb2的抗体或其抗原结合片段 |
| CN119619509A (zh) * | 2023-09-05 | 2025-03-14 | 中日友好医院(中日友好临床医学研究所) | 一种结直肠癌治疗靶点和血清标志物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| EP2160409A1 (en) * | 2007-05-24 | 2010-03-10 | Ablynx N.V. | Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
| EP2552962B1 (en) | 2010-03-26 | 2016-03-23 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA3218106A1 (en) * | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| EP4219559A3 (en) * | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| EP3740224A4 (en) * | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
-
2020
- 2020-09-18 CN CN202080065196.6A patent/CN115066435B/zh active Active
- 2020-09-18 BR BR112022004534A patent/BR112022004534A2/pt unknown
- 2020-09-18 JP JP2022517990A patent/JP7627687B2/ja active Active
- 2020-09-18 CA CA3154450A patent/CA3154450A1/en active Pending
- 2020-09-18 US US17/762,270 patent/US20230235050A1/en not_active Abandoned
- 2020-09-18 EP EP20771598.8A patent/EP4031572A1/en active Pending
- 2020-09-18 MX MX2022003365A patent/MX2022003365A/es unknown
- 2020-09-18 KR KR1020227012733A patent/KR20220128332A/ko active Pending
- 2020-09-18 WO PCT/EP2020/076198 patent/WO2021053199A1/en not_active Ceased
- 2020-09-18 AU AU2020351274A patent/AU2020351274A1/en active Pending
-
2022
- 2022-03-20 IL IL291506A patent/IL291506A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511936A5 (enExample) | ||
| JP2022093564A5 (enExample) | ||
| TWI712423B (zh) | 抗ｔｒｏｐ２抗體-藥物結合物之製造方法 | |
| JP7755635B2 (ja) | 抗ｈｅｒ２抗体 | |
| JP2020534250A5 (enExample) | ||
| JP2025163055A5 (enExample) | ||
| JP5749330B2 (ja) | 癌を治療するためのヒト化抗ｃｘｃｒ４抗体 | |
| JP2020501531A5 (enExample) | ||
| JP5463036B2 (ja) | 可溶性ｃｅａに対する抵抗性を有する医薬抗体組成物 | |
| JP2021511811A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2020507571A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| JP2012504401A (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2017530692A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| EP2945968B1 (en) | Antibodies that bind to jagged 1 | |
| JP2023538114A5 (enExample) | ||
| JP2022527173A5 (enExample) | ||
| CN116096756A (zh) | 针对ilt2的抗体及其用途 |